Mirapex News and Research

RSS
Parkinson's disease medications could lead to impulse control disorders

Parkinson's disease medications could lead to impulse control disorders

Teva second quarter net sales increase 11% to $4.2 billion

Teva second quarter net sales increase 11% to $4.2 billion

Parkinson's disease drugs may lead to impulse control disorders

Parkinson's disease drugs may lead to impulse control disorders

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mylan receives final FDA approval for Pramipexole Dihydrochloride Tablets

Mylan receives final FDA approval for Pramipexole Dihydrochloride Tablets

Teva second-quarter net sales increase 12% to $3.8 billion

Teva second-quarter net sales increase 12% to $3.8 billion

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Pramipexole ER uptake to be inhibited by availability of generic version

Pramipexole ER uptake to be inhibited by availability of generic version

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

New experimental treatment for Tourette's syndrome

New experimental treatment for Tourette's syndrome

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr announces favorable ruling in Mirapex patent challenge

Barr announces favorable ruling in Mirapex patent challenge

Barr receives approval for generic Mirapex tablets

Barr receives approval for generic Mirapex tablets

Parkinson's drug Mirapex accused of causing gambling addiction

Parkinson's drug Mirapex accused of causing gambling addiction

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

Clinical trial established that two drugs, levodopa and pramipexole, are both viable initial treatments for Parkinson's disease

Clinical study compares treatments in early Parkinson's disease

Clinical study compares treatments in early Parkinson's disease